April 1, 2024 09:21 AM EDTUpdated 09:45 AM

Carlyle’s Abingworth will help fund Teva’s Phase 3 asthma rescue inhaler

Kyle LaHucik

Senior Reporter

Abingworth will provide up to $150 million to help fund Teva Pharmaceuticals’ development of an asthma rescue inhaler, the companies said Monday morning.

The asset …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Carlyle’s Abingworth will help fund Teva’s Phase 3 asthma rescue inhaler

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Car­lyle’s Abing­worth will help fund Te­va’s Phase 3 asth­ma res­cue in­haler

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Carlyle’s Abingworth will help fund Teva’s Phase 3 asthma rescue inhaler